Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
New surgical techniques and new systemic treatments have come together to increase the number of patients with metastatic colorectal cancer who have been cured. There is great hope that new targeted agents will further increase our success, both through improved therapeutic outcomes and better selection of patients for this more invasive and aggressive approach. A summary of this current clinical data is presented herein to establish our current standards and to guide us toward our future goals. We are increasingly managing patients with a multidisciplinary approach, a critical element in our success. Biologic therapies will continue to play an important role in the management of these patients.
Marshall
John L
JL
Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. marshalj@georgetown.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D009362:Neoplasm Metastasis / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors